This prospective study aims to evaluate the effects of mega-dose vitamin D pulse therapy followed by maintenance therapy on seizure frequency, fatigue, and quality of life in patients with epilepsy. Participants will receive vitamin D supplementation, and clinical outcomes will be assessed over time to determine its potential benefits on seizure control and patient-reported outcomes.
This is a prospective study designed to investigate the clinical effects of vitamin D supplementation in patients with epilepsy. Participants will receive a high-dose vitamin D pulse therapy followed by maintenance dosing. The study will assess changes in seizure frequency, fatigue, and quality of life over the study period. Clinical data will be collected longitudinally, and comparisons will be made to evaluate treatment effectiveness. This study aims to explore whether vitamin D supplementation can serve as a potential adjunctive therapy in epilepsy management.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
200
National Cheng Kung University Hospital
Tainan, Taiwan
RECRUITINGseizure frequency
Seizure frequency (number of seizures per month), assessed at baseline, 1 month, and 3 months after initiation of vitamin D therapy.
Time frame: three time points: before starting the medication, one month after starting the medication, and three months after starting the medication.
Quality of life score (QOLIE-31)
Quality of life, assessed using a validated questionnaire (e.g., QOLIE-31), measured at baseline and 3 months after treatment.
Time frame: before starting the medication and again three months after treatment
Fatigue severity score (Fatigue Severity Scale)
Fatigue severity, assessed using a standardized fatigue scale (e.g., Fatigue Severity Scale), measured at baseline and 3 months after treatment.
Time frame: before starting the medication and three months after starting it.
Serum vitamin D levels (25-hydroxyvitamin D)
Serum biochemical parameters (including vitamin D levels), measured at baseline, 1 month, and 3 months after treatment.
Time frame: three time points: before starting the medication, one month after starting it, and three months after starting it.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.